The body as a manufacturer of endostatin
- 1 April 1999
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 17 (4) , 336-337
- https://doi.org/10.1038/7890
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin geneNature Biotechnology, 1999
- Behind the Headlines of Endostatin's Ups and DownsScience, 1999
- Antiangiogenic gene therapyProceedings of the National Academy of Sciences, 1998
- Antiangiogenic tumour therapy: will it work?Trends in Pharmacological Sciences, 1998
- A triploblast origin for Myxozoa?Nature, 1998
- Gene therapy strategies for tumor antiangiogenesisJNCI Journal of the National Cancer Institute, 1998
- Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor GrowthCell, 1997
- Regulatable Promoters for Use in Gene Therapy Applications: Modification of the 5′-Flanking Region of the CFTR Gene with Multiple cAMP Response Elements to Support Basal, Low-Level Gene Expression That Can Be Upregulated by Exogenous Agents That Raise Intracellular Levels of cAMPHuman Gene Therapy, 1996
- Transfer of Genes to Humans: Early Lessons and Obstacles to SuccessScience, 1995
- Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinomaCell, 1994